Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection

Journal of Virology

Volumn 76, Issue 22, 2002, Pages 11561-11569

  De Swart, Rik L ^a   Kuiken, Thijs ^a   Timmerman, Helga H ^a   Van Amerongen, Geert ^a   Van den Hoogen, Bernadette G ^a   Vos, Helma W ^a   Neijens, Herman J ^a   Andeweg, Arno C ^a   Osterhaus, Albert D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; INTERLEUKIN 13; INTERLEUKIN 5; MEASLES VACCINE; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; EOSINOPHILIA; HUMAN; HUMAN CELL; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOPATHOLOGY; LYMPHOCYTE PROLIFERATION; MACACA; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION; TH2 CELL; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; WILD TYPE;

EID: 0036828165     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.22.11561-11569.2002     Document Type: Article

References (43)

1. Belshe, R. B., L. S. Richardson, W. T. London, D. L. Sly, J. H. Lorfeld, E. Camargo, D. A. Prevar, and R. M. Chanock. 1977. Experimental respiratory syncytial infection of four species of primates. J. Med. Virol. 1:157-162.
2. Boelen, A., A. C. Andeweg, J. Kwakkel, W. Lokhorst, T. M. Bestebroer, J. Dormans, and T. G. Kimman. 2000. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 19:982-991.
3. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1351. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 3rd Ed. Lippincott-Raven Publishers, Philadelphia, Pa.
4. Corry, D. B. 1999. IL-13 in allergy: Home at last. Curr. Opin. Immunol. 11:610-614.
5. Crowe, J. E., Jr. 2002. Respiratory syncytial virus vaccine development. Vaccine 20:S32-S37.
6. De Waal Malefyt, R., C. G. Figdor, R. Huijbens, S. Mohan-Peterson, B. Bennett, J. Culpepper, W. Dang, G. Zurawski, and J. E. De Vries. 1993. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J. Immunol. 151:6370-6381.
7. Domachowske, J. B., and H. F. Rosenberg. 1999. Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment. Clin. Microbiol. Rev. 12:298-309.
8. Fulginiti, V. A., and J. H. Arthur. 1969. Altered reactivity to measles virus. Skin test reactivity and antibody response to measles virus antigens in recipients of killed measles virus vaccine. J. Pediatr. 75:609-616.
9. Fulginiti, V. A., J. J. Eller, A. W. Downte, and C. H. Kempe. 1967. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated virus vaccines. JAMA 202:101-106.
10. Gershwin, L. J., E. S. Schelegle, R. A. Gunther, M. L. Anderson, A. R. Woolums, D. R. Larochelle, G. A. Boyle, K.E. Friebertshauser, and R. S. Singer. 1998. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16:1225-1236.
11. Graham, B. S. 1995. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am. J. Respir. Crit. Care Med. 152:S63-S66.
12. Greenfeder, S., S. P. Umland, F. M. Cuss, R. W. Chapman, and R. W. Egan. 2001. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir. Res. 2:71-79.
13. Grunig, G., M. Warnock, A. E. Wakil, R. Venkayya, F. Brombacher, D. M. Rennick, D. Sheppard, M. Mohrs, D. D. Donaldson, R. M. Locksley, and D. B. Corry. 1998. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261-2263.
14. Hirst, S. J. 2000. Airway smooth muscle as a target in asthma. Clin. Exp. Allergy 30(Suppl. 1):54-59.
15. Johnson, T. R., and B. S. Graham. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73:8485-8495.
16. Kakuk, T. J., K. Soike, R. J. Brideau, R. M. Zaya, S. L. Cole, J.-Y. Zhang, E. D. Roberts, P. A. Wells, and M. W. Wathen. 1993. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vacine. J. Infect. Dis. 167:553-561.
17. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. E. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
18. Kim, H. W., S. L. Leikin, J. Arrobio, C. D. Brandt, R. M. Chanock, and R. H. Parrott. 1976. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr. Res. 10:75-78.
19. Krause, P. J., J. D. Cherry, M. J. Naiditch, J. Deseda-Tous, and E. J. Walbergh. 1978. Revaccination of previous recipients of killed measles vaccine: Clinical and immunologic studies. J. Pediatr. 93:565-571.
20. Lukacs, N. W., K. K. Tekkanat, A. Berlin, C. M. Hogaboam, A. Miller, H. Evanoff, P. Lincoln, and H. Maassab. 2001. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms. J. Immunol. 167:1060-1065.
21. Mazzarella, G., L. Stendardi, M. Grazzini, and G. Scano. 2000. Mechanisms involved in airway obstruction: The role of smooth muscle. Allergy 55(Suppl. 61):46-48.
22. Openshaw, P. J., S. L. Clarke, and F. M. Record. 1992. Pulmonary eosinophilic response to respiratory syncytial virus in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:493-500.
23. Openshaw, P. J. M., F. J. Culley, and W. Olszewska. 2002. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20:S27-S31.
24. a.Ostler, T., and S. Ehl. 2002. A cautionary note on experimental artifacts induced by fetal calf serum in a viral model of pulmonary eosinophilia. J. Immunol. Methods 268:211-218.
25. Ottolini, M. G., D. D. Porter, V. G. Hemming, and G. A. Prince. 2000. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunol. 13:231-236.
26. Peebles,R. S., Jr., K. Hashimoto, R. D. Collins, K. Jarzecka, J. Furlong, D. B. Mitchell, J. R. Sheller, and B. S. Graham. 2001. Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges. J. Infect. Dis. 184:1374-1379.
27. Peebles, R. S., Jr., J. R. Sheller, R. D. Collins, K. Jarzecka, D. B. Mitchell, and B. S. Graham. 2000. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J. Infect. Dis. 182:671-677.
28. Piedra, P. A., P. R. Wyde, W. L. Castleman, M. W. Ambrose, A. M. Jewell, D. J. Speelman, and S. W. Hildreth. 1993. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine 11:1415-1423.
29. Polack, F. P., P. G. Auwaerter, S. H. Lee, H. C. Nousari, A. Valsamakis, K. M. Leiferman, A. Diwan, R. J. Adams, and D. E. Griffin. 1999. Production of atypical measles in rhesus macaques: Evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5:629-634.
30. Polack, F. P., S. J. Hoffman, W. J. Moss, and D. E. Griffin. 2002. Altered synthesis of interleukin-12 and type 1 and type 2 cytokines in rhesus macaques during measles and atypical measles. J. Infect. Dis. 185:13-19.
31. Ponnuraj, E. M., A. R. Hayward, A. Raj, H. Wilson, and E. A. F. Simoes. 2001. Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine. J. Gen. Virol. 82:2663-2674.
32. Power, U. F., T. N. Nguyen, E. Rietveld, R. L. de Swart, J. Groen, A. D. M. E. Osterhaus, R. de Groot, N. Corvaia, A. Beck, N. Bouveret-le-Cam, and J.-Y. Bonnefoy. 2001. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184:1456-1460.
33. Prince, G. A., S. J. Curtis, K. C. Yim, and D. D. Porter. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82:2881-2888.
34. Prince, G. A., A. B. Jenson, V. G. Hemming, B. R. Murphy, E. E. Walsh, R. L. Horswood, and R. M. Chanock. 1986. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57:721-728.
35. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
36. Simoes, E. A. F., A. R. Hayward, E. M. Ponnuraj, J. P. Straumanis, K. R. Stenmark, H. L. Wilson, and P. G. Babu. 1999. Respiratory syncytial virus infects the Bonnet monkey, Macaca radiata. Pediatr. Dev. Pathol. 2:316-326.
37. Stittelaar, K. J., L. S. Wyatt, R. L. de Swart, H. W. Vos, J. Groen, G. van Amerongen, R. S. van Binnendijk, S. Rozenblatt, B. Moss, and A. D. M. E. Osterhaus. 2000. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles vaccine in the presence of passively acquired antibodies. J. Virol. 74:4236-4243.
38. Tekkanat, K. K., H. F. Maassab, D. S. Cho, J. J. Lai, A. John, A. Berlin, M. H. Kaplan, and N. W. Lukacs. 2001. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J. Immunol. 166:3542-3548.
39. van Binnendijk, R. S., M. C. M. Poelen, G. van Amerongen, P. De Vries, and A. D. M. E. Osterhaus. 1997. Protective immunity in macaques vaccinated with live attenuated, recombinant and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:524-534.
40. van Binnendijk, R. S., R. W. J. van der Heijden, G. van Amerongen, F. G. C. M. UytdeHaag, and A. D. M. E. Osterhaus. 1994. Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J. Infect. Dis. 170:443-448.
41. Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson. 1996. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:2852-2860.
42. Weltzin, R., V. Traina-Dorge, K. Soike, J.-Y. Zhang, P. Mack, G. Soman, G. Drabik, and T. P. Monath. 1996. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J. Infect. Dis. 174:256-261.
43. Wills-Karp, M., J. Luyimbazi, X. Xu, B. Schofield, T. Y. Neben, C. L. Karp, and D. D. Donaldson. 1998. Interleukin-13: Central mediator of allergic asthma. Science 282:2258-2261.